A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Phase 3
586
about 3.6 years
60–85
28 sites in CA, CO, DC +14
About this study
Researchers are testing whether KarXT plus KarX-EC, a treatment, improves cognitive function in people with Alzheimer's disease. The trial will last 1320 days and involve approximately 586 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take KarX-EC
- 3.Take KarXT
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11)
Secondary: Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL), Change from baseline in neuro psychiatric inventory (NPI) total score, Number of participants with AEs leading to death, Number of participants with AEs leading to study discontinuation, Number of participants with AEs leading to study intervention discontinuation, Number of participants with adverse event of special interest (AESIs), Number of participants with adverse events (AEs), Number of participants with serious adverse events (SAEs)
Neurology